The effect of carnitine for chronic liver disease or liver cirrhosis with hyperammonemia

The effect of carnitine for chronic liver disease or liver cirrhosis with hyperammonemia - The effect of carnitine for hyperammonemia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025034

Enrollment

140

Registered

2016-11-29

Start date

2016-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease with hyperammonemia

Interventions

standard therapy treated generaly carnitine administration (1000mg/day, 3 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Informed consent was obtained 2.Patients has not receive carnitine before 2 weeks 3.chronic liver damage and liver cirrhosis who has serum ammonia more than 60ug/dL 4.hepatic encephalopathy or positive of number conection test B

Exclusion criteria

Exclusion criteria: 1.GI tract bleeding 2.Patients experienced adverse events 3.Giant shunt of vessels 4.dementia 5.malignat tumor which is uncontroled 6.Allergic reaction for carnitine 7.Patients who administrate drugs that introduce hyperammonemia 8.Patients receive dialysis 9.Patients who is pregnant

Design outcomes

Primary

Measure	Time frame
Decrease of ammonia after carnitine administration	—

Countries

Japan

Contacts

Public ContactShunsuke Nojiri

Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

snojiri@med.nagoya-cu.ac.jp+81-52-853-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026